Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [¹⁸F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 Trial.

ABSTRACT:

Purpose

The clinical significance of medullary abnormalities in the appendicular skeleton detected by computed tomography (CT) in patients with multiple myeloma (MM) remains incompletely elucidated. This study aims to validate novel low-dose CT-based methods for quantifying myeloma bone marrow (BM) volume in the appendicular skeleton of MM patients undergoing [¹⁸F]FDG PET/CT.

Materials and methods

Seventy-two newly diagnosed, transplantation eligible MM patients enrolled in the randomised phase 3 GMMG-HD7 trial underwent whole-body [¹⁸F]FDG PET/CT prior to treatment and after induction therapy with either isatuximab plus lenalidomide, bortezomib, and dexamethasone or lenalidomide, bortezomib, and dexamethasone alone. Two CT-based methods using the Medic

SUBMITTER: Sachpekidis C 

PROVIDER: S-EPMC12860749 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature